Pfizer's (PFE.US) $43 billion Seagen (SGEN.US) deal wins unconditional EU approval. As it was concluded by European lawmakers, deal wouldn't raise competition concerns or higher prices for oncology drugs.
Source: xStation5
US OPEN: Market extends decline at the end of the week
Constellation Energy: Mixed Results for Q3 2025
More Expensive Chips, More Expensive Devices – TSMC is Changing the Rules!
Hensoldt Rises Thanks to Record Backlog and Growth Plans!
This content has been created by XTB S.A. This service is provided by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, entered in the register of entrepreneurs of the National Court Register (Krajowy Rejestr Sądowy) conducted by District Court for the Capital City of Warsaw, XII Commercial Division of the National Court Register under KRS number 0000217580, REGON number 015803782 and Tax Identification Number (NIP) 527-24-43-955, with the fully paid up share capital in the amount of PLN 5.869.181,75. XTB S.A. conducts brokerage activities on the basis of the license granted by Polish Securities and Exchange Commission on 8th November 2005 No. DDM-M-4021-57-1/2005 and is supervised by Polish Supervision Authority.
